ACRS / Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps more_horizontal

An analyst raised his price target on the biotech. He also maintained his buy recommendation on the stock. more_horizontal

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to more_horizontal

Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be more_horizontal

Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough. more_horizontal

The biotech has completed enrollment in the next phase of an important development program. It is aiming to get a rheumatoid arthritis drug to market. more_horizontal

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to more_horizontal

WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developi more_horizontal